NSCLC: First-line, maintenance or second and greater-line treatment after failure of ≥1 chemotherapy regimen of pts with mNSCLC and EGFR exon 19 deletions or L858R mutationMetastatic pancreatic cancer: in combination with gemcitabine. This evidence concerns the gene EGFR and familial pancreatic carcinoma.